Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEODOC study of autologous tumor lysate-loaded XP-DC with chemotherapy in epithelial ovarian cancer
NL-OMON54480Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2023
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of autologous whole tumor lysate-loaded XP-DC in epithelial ovarian cancer (EOC) and High-Grade Serous Ovarian Cancer (HGSOC), sponsored by Radboud University Medical Center. Started Mar 2023; status: recruiting.
02
Drugs
autologous whole tumor lysate-loaded XP-DC
03
Conditions
epithelial ovarian cancer (EOC)High-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on NL-OMON54480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54480.